ADHD

Discover how Mentavi Health's innovative ADHD assessment enhances diagnosis speed, accuracy, and patient engagement in mental health care.

A recent study reveals higher substance use disorder rates in individuals with ADHD, highlighting significant sex differences and the impact of comorbid psychiatric conditions.

Reproductive psychiatrist Sarah Oreck, MD, MS challenges the FDA's claims linking acetaminophen use in pregnancy to autism and ADHD, advocating for informed maternal care.

Combining cognitive behavioral therapy with medication enhances ADHD treatment in adults, showing significant benefits within 3 months.

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

Our August theme: the complexities of ADHD, including assessment, treatment options, and comorbidities. Share your insights!

Research reveals significant risks of neonatal complications linked to in utero valproic acid exposure, emphasizing the need for careful management during pregnancy.

Cingulate secures a $4.3 million FDA fee waiver for its innovative ADHD treatment, CTx-1301, enhancing patient care with extended efficacy.

The FDA has updated ADHD stimulant labels, highlighting weight loss risks in children under 6. Stephen Mateka, DO, shares his updated treatment strategies.

Marc Potenza, PhD, MD, explores the impact of online social activity on ADHD symptoms in adolescents, revealing significant gender differences in brain development and attention.

The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals.

Panelists discuss the critical role of pediatricians in attention-deficity/hyperactivity disorder (ADHD) diagnosis and treatment challenges.

Panelists discuss how attention-deficity/hyperactivity disorder (ADHD) risk factors include genetic, environmental, and socioeconomic influences.

New research reveals the complex relationship between ADHD and bipolar disorder, highlighting genetic overlaps and treatment considerations for effective management.

Panelists discuss how an attention-deficity/hyperactivity disorder (ADHD) diagnosis impacts families through stress and challenges but can also provide relief and understanding. They address quality-of-life effects including academic performance, family functioning, driving safety, and the need for structure and routine management.

Panelists discuss how diagnostic challenges include ensuring symptoms are developmentally appropriate, distinguishing attention-deficity/hyperactivity disorder (ADHD) from other conditions such as depression and anxiety and using tools such as the NICHQ Vanderbilt Assessment Scales and Connors Comprehensive Behavior Rating Scale to assess symptoms across multiple settings.

Panelists discuss how the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for attention-deficity/hyperactivity disorder (ADHD) require at least 6 of 9 symptoms in either inattentive or hyperactive-impulsive domains, with inattentive presentations often unrecognized in girls and highly intelligent students in particular.

Panelists discuss how attention-deficity/hyperactivity disorder (ADHD) presents in a 10-year-old boy with combined presentation symptoms, emphasizing the importance of seeing difficulties across multiple settings and noting the genetic component when family history is present.

Busy Philipps and Ann Childress, MD, explore the unique challenges women face in ADHD diagnosis, highlighting personal stories and the importance of treatment.

How does adult ADHD differ from pediatric ADHD? Jeffrey Newcorn, MD, shared his expertise at the 2025 APA Annual Meeting.

Effective diagnosis and treatment of comorbid disorders in patients with bipolar enhance care and lead to more optimal mental health outcomes.

This critical analysis of recent ADHD coverage challenges misconceptions about treatment, emphasizing the need for a comprehensive approach to mental health.

A panelist discusses how attention deficit/hyperactivity disorder (ADHD) as a common neurodevelopmental disorder characterized by inattention and hyperactive-impulsive behavior, affecting approximately 10.5% of children in the US aged 3 to 17 years with higher prevalence in adolescents and boys, highlighting its various symptoms, potential causes including genetic factors, and mentioning upcoming discussions about treatment options and transitioning care from pediatric to adult settings.

Here are highlights from this week in Psychiatric Times, including positive clinical trial news for an ADHD treatment and an exclusive interview on the joint statement defending psychotropic medication safety.

The FOCUS phase 3 trial of solriamfetol for the treatment of ADHD demonstrated statistically significant improvements in ADHD symptoms and disease severity.